Influence of recombinant human erythropoietin therapy on plasma endothelin-1 levels during hemodialysis.


The correction of anemia with human recombinant erythropoietin (rHuEPO) in end stage renal disease is associated with hypertension in about one third of hemodialysis patients. The pathogenesis of the rHuEPO-induced hypertension is still uncertain, though evidence of the involvement of endothelial cells has emerged. The aim of this study was to determine… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.